Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 1-3, 2010, Pages 23-29

  Khier, Sonia ^a   Deleuze Masquéfa, Carine ^a   Moarbess, Georges ^a   Gattacceca, Florence ^a   Margout, Delphine ^a   Solassol, Isabelle ^b   Cooper, Jean François ^c   Pinguet, Frédéric ^b   Bonnet, Pierre Antoine ^a   Bressolle, Françoise M M ^a  

^a UNIV MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIVERSITÉ DE PERPIGNAN   (France)

Author keywords

Imidazo 1,2 a quinoxaline; In vitro and in vivo cytotoxic activities; LC ESI MS; Melanoma; Pharmacokinetics; Sub acute toxicity

Indexed keywords

1 (2 PHENETHYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; EAPB 0202; EAPB 0203; FOTEMUSTINE; IMIDAZO[1,2 A]QUINOXALINE DERIVATIVE; IMIQUIMOD; N METHYL 1 (2 PHENETHYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MELANOMA; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SURVIVAL TIME; TOXICITY TESTING; TUMOR XENOGRAFT; VALIDATION PROCESS;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; MICE; MICE, NUDE; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; QUINOXALINES; RATS; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74149085534     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.10.006     Document Type: Article

References (26)

1. Bressolle F., Bromet-Petit M., and Audran M. Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. J. Chromatogr. B: Biomed. Appl. 686 (1996) 3-10
2. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993) 1093-1095
3. Deleuze-Masquéfa C., Gerebtzoff G., Subra G., Fabreguettes J.R., Ovens A., Carraz M., Strub M.P., Bompart J., George P., and Bonnet P.A. Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors. Bioorg. Med. Chem. 12 (2004) 1129-1139
4. Deleuze-Masquéfa C., Moarbess G., Khier S., David N., Gayraud-Paniagua S., Bressolle F., Pinguet F., and Bonnet P.A. New imidazo[1,2-a]quinoxaline derivatives. Synthesis and in vitro activity against human melanoma. Eur. J. Med. Chem. 44 (2009) 3406-3411
5. Deleuze-Masquéfa, C., Moarbess, G., Pinguet, F., Bazarbachi, A., Bonnet, P.A., 2009b. Imidazo[1,2-a]quinoxalines et leurs dérivés pour le traitement des cancers. Patent no. FR 2921927.
6. Deleuze-Masquéfa, C., Moarbess, G., Pinguet, F., Bazarbachi, A., Bressolle, F., Bonnet, P.A., 2009c. Imidazo[1,2-a]quinoxalines et leurs dérivés pour le traitement des cancers. Patent no. WO 2009043934.
7. Farenc C., Fabreguette J.R., and Bressolle F. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput. Biomed. Res. 33 (2000) 315-330
8. Greinert R. Skin cancer: new markers for better prevention. Pathobiology 76 (2009) 64-81
9. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., and Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3 (2002) 196-200
10. Hengge U.R., and Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br. J. Dermatol. 149 (2003) 15-19
11. Kang H.Y., Park T.J., and Jin S.H. Imiquimod, a toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J. Invest. Dermatol. 129 (2009) 243-246
12. Khier S., Moarbess G., Deleuze-Masquéfa C., Margout D., Solassol I., Pinguet F., Bonnet P.A., and Bressolle F. Quantitation of two imidazo[1,2-a]quinoxaline derivatives (EAPB0503 and EAPB0603) with anti-tumoral activity in human and rat plasma by liquid chromatography-electrospray mass spectrometry. Application to a pharmacokinetic study. J. Sep. Sci. 32 (2009) 1363-1373
13. Marchi I., Rudaz S., Selman M., and Veuthey J.L. Evaluation of the influence of protein precipitation prior to on-line SPE-LC-API/MS procedures using multivariate data analysis. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 845 (2007) 244-252
14. Moarbess G., Deleuze-Masquéfa C., Bonnard V., Paniagua S., Vidal J.R., Bressolle F., Pinguet F., and Bonnet P.A. In vitro and in vivo antitumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg. Med. Chem. 16 (2008) 6601-6610
15. Moarbess G., El-Hajj H., Kfoury Y., El-Sabban M.E., Lepelletier Y., Hermine O., Deleuze-Masquéfa C., Bonnet P.A., and Bazarbachi A. EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase dependent apoptosis in T cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Blood 111 (2008) 3770-3777
16. Morjaria S., Deleuze-Masquéfa C., Lafont V., Gayraud S., Bompart J., Bonnet P.A., and Dornand J. Impairment of TNF-alpha production and action by imidazo[1,2-a] quinoxalines, a derivative family which displays potential anti-inflammatory properties. Int. J. Immunopathol. Pharmacol. 19 (2006) 525-538
17. RDPP. Pk-fit Computer Program, Version 2.1 (1999), RDPP, Montpellier, France
18. Rudy S.J. Imiquimod (Aldara): modifying the immune response. Dermatol. Nurs. 14 (2002) 268-270
19. Sauder D.N. Imiquimod: modes of action. Br. J. Dermatol. 149 Suppl. 66 (2003) 5-8
20. Schön M.P., Wienrich B.G., Drewniok C., Bong A.B., Eberle J., Geilen C.C., Gollnick H., and Schön M. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J. Invest. Dermatol. 122 (2004) 1266-1276
21. Schön M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., Benninghoff B., Slade H.B., Gollnick H., and Schön M.P. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl. Cancer Inst. 95 (2003) 1138-1149
22. Spaner D.E., Miller R.L., Mena J., Grossman L., Sorrenti V., and Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk. Lymphoma 46 (2005) 935-939
23. Steinmann A., Funk J.O., Schuler G., and Von den Driech P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J. Am. Acad. Dermatol. 43 (2000) 555-556
24. van Egmond S., Hoedemaker C., and Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int. J. Dermatol. 46 (2007) 318-319
25. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., and Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24 (2007) 1962-1973
26. Xu X., Mei H., Wang S., Zhou Q., Wang G., Broske L., Pena A., and Korfmacher W.A. A study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays. Rapid Commun. Mass Spectrom. 19 (2005) 2643-2650